Abstract: Provided is a method of treating the health-related quality-of-life (HRQOL) symptoms of a lung disease, comprising the administration of an inhalable aerosol of aztreonam lysine. The method is suitable for the short term and sustainable long term treatment of HRQOL symptoms.
Abstract: The invention relates to methods for the treatment of a sleep disorder comprising administering a compound of formula (I): wherein all variables are as defined herein.
Type:
Grant
Filed:
January 18, 2006
Date of Patent:
March 18, 2008
Assignee:
SmithKline Beecham Corporation
Inventors:
Giuseppe Alvaro, Romano Di Fabio, Riccardo Giovannini, Giuseppe Guercio, Yves St-Denis, Antonella Ursini
Abstract: The present invention provides compounds of formula (I): pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.
Abstract: The invention relates to Form physical forms of 5,6-dichloro-2-(isopropylamino)-1-?-L-ribofuranosyl-1H-benzimidazole, pharmaceutical compositions comprising the same, and their use in medical therapy.
Type:
Grant
Filed:
October 29, 2001
Date of Patent:
November 20, 2007
Assignee:
SmithKline Beecham Corporation
Inventors:
Bobby Neal Glover, Lian-Feng Huang, Robert William Lancaster, Stacey Todd Long, Michele Catherine Rizzolio, Eric Allen Schmitt, Barry Riddle Sickles
Abstract: The present invention provides compounds of formula (I): wherein each R independently represents a halogen atom or a C1-4 alkyl group; R1 represents a C1-4 alkyl group; R2 represents hydrogen or a C1-4 alkyl group; R3 represents hydrogen or C1-4 alkyl group; R4 represents a trifluoromethyl group; R5 represents hydrogen, a C1-4 alkyl group or C(O)R6; R6 represents C1-4 alkyl, C3-7 cycloalkyl, NH(C1-4 alkyl) or N(C1-4alkyl)2; m is zero or an integer from 1 to 3; n is an integer from 1 to 3; or a pharmaceutically acceptable salt or solvate thereof; compositions containing the same, processes for their preparation and methods for their use in the treatment of conditions mediated by tachykinins.
Abstract: The present invention relates to piperidine derivatives of formula (I): wherein R represents halogen or C1-4 alkyl; R1 represents hydrogen or C1-4 alkyl; R2 represents hydrogen, C1-4 alkyl; R3 represents hydrogen, C1-4 alkyl; R4 represents trifluoromethyl, C1-4 alkyl, C1-4 alkoxy, trifluoromethoxy or halogen; R5 represents hydrogen, C1-4 alkyl, C3-7 cycloalkyl, C(O)R6 or S(O)2R6; R6 represents C1-4 alkyl or C3-7 cycloalkyl; m is zero or an integer from 1 to 3; n is an integer from 1 to 3; p is an integer from 1 to 2; X and Y are independently C(O) or CH2; provided that i) X and Y are not both C(O) and ii) when X and Y are both CH2 and p is 1, R5 is not hydrogen, C1-4 alkyl or C(O)R6; and pharmaceutically acceptable salts and solvates thereof, the process for their preparation and their use in the treatment of conditions mediated by tachykinins.
Abstract: The present invention provides compounds of formula (I): pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.
Abstract: The present invention relates to piperazine of formula (I) wherein R represents halogen, C1-4 alkyl, trifluoromethoxy or trifluoromethyl; R1 is trifluoromethyl, C1-4 alkyl, C1-4 alkoxy, halogen or trifluoromethoxy; R2 is hydrogen, C1-4 alkyl or C2-6 alkenyl; R3 represents hydrogen or C1-4 alkyl; n and m are independently 0 or an integer from 1 to 3; and pharmaceutically acceptable salts and solvates thereof, process for their preparation and their use in the treatment of condition mediated by tachykinins and/or by selective inhibition of the serotonin reuptake transporter protein.
Type:
Grant
Filed:
August 13, 2002
Date of Patent:
May 8, 2007
Assignee:
Glaxo Group Limited
Inventors:
Giuseppe Alvaro, Torquil I. M. Jack, Maria Elvira Tranquillini
Abstract: The present invention provides compounds of formula (I): wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.
Abstract: The present invention relates to piperidine derivatives of formula (I): R represents halogen or C1-4 alkyl R1 represents C1-4 alkyl; R2 or R3 independently represent hydrogen or C1-4 alkyl; R4 represents trifluoromethyl, C1-4 alkyl, C1-4 alkoxy, trifluoromethoxy or halogen; R5 represents hydrogen, C1-4 alkyl or C3-7 cycloalkyl; R6 is hydrogen and R7 is a radical of formula (W): ?or R6 is a radical of formula (W) and R7 is hydrogen; X represents CH2, NR5 or O; Y represents Nitrogen and Z is CH or Y represents CH and Z is Nitrogen; A represents C(O) or S(O)q, provided that when Y is nitrogen and Z is CH, A is not S(O)q; m is zero or an integer from 1 to 3; n is an integer from 1 to 3; p and q are independently an integer from 1 to 2; and pharmaceutically acceptable salts and solvates thereof. The process for their preparation and their use in the treatment of a condition mediated by tachykinins.
Type:
Grant
Filed:
February 10, 2003
Date of Patent:
March 13, 2007
Assignee:
Glaxo Group Limited
Inventors:
Giuseppe Alvaro, Romano Di Fabio, Maria Elvira Tranquillini, Simone Spada
Abstract: The present invention provides compounds of formula (I) wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents
Abstract: Compounds of Formula (I): salts or solvates or physiologically functional derivatives thereof, wherein Z is CH or N, and R1, R2, and R4 are various substituent groups, are protein kinase inhibitors
Type:
Grant
Filed:
August 22, 2001
Date of Patent:
January 23, 2007
Assignee:
Glaxo Group Limited
Inventors:
Michael John Alberti, Ian Robert Baldwin, Mui Cheung, Stuart Cockerill, Stephen Flack, Philip Anthony Harris, David Kendall Jung, Gregory Peckham, Michael Robert Peel, Jennifer Gabriel Badiang, Kirk Stevens, James Marvin Veal
Abstract: The present invention provides compounds of formula (I): wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.
Type:
Grant
Filed:
November 26, 2001
Date of Patent:
January 16, 2007
Assignee:
SmithKline Beecham Corporation
Inventors:
F. Leslie Boyd, Stanley D Chamberlain, Mui Cheung, Kristjan Gudmundsson, Philip Anthony Harris, Brian A Johns, David Kendall Jung, Michael Robert Peel, Jennifer G Badiang, Connie Jo Sexton
Abstract: The present invention provides compounds of formula (I): wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.
Type:
Grant
Filed:
March 18, 2005
Date of Patent:
January 9, 2007
Assignee:
SmithKline Beecham Corporation
Inventors:
Stanley D. Chamberlain, Kristjan Gudmundsson, Brian A. Johns
Abstract: The present invention provides compounds of formula (I): wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.
Abstract: The present invention provides compounds of formula (I): pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.
Type:
Grant
Filed:
March 5, 2002
Date of Patent:
December 26, 2006
Assignee:
SmithKline Beecham Corporation
Inventors:
F. Leslie Boyd, Kristjan Gudmundsson, Brian A Johns
Abstract: The present invention provides compounds of formula (I): pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.
Type:
Grant
Filed:
March 21, 2002
Date of Patent:
November 28, 2006
Assignee:
SmithKline Beecham Corporation
Inventors:
Mui Cheung, Kristjan Gudmundsson, Brian A. Johns
Abstract: wherein R represents a halogen atom or a C1-4 alkyl group; R1 represents a C1-4 alkyl group; R2 represents hydrogen or a C1-4 alkyl group; R3 represents hydrogen, or a C1-4 alkyl group; R4 represents a trifluoromethyl group; R5 represents hydrogen, a C1-4 alkyl group or C(O)R6; R6 represents C1-4 alkyl, C3-7 cycloalkyl, NH(C1-4 alkyl) or N(C1-4alkyl)2; m is zero or an integer from 1 to 3; n is an integer from 1 to 3 and pharmaceutically acceptable salts and solvates thereof; to processes for their preparation and their use in the treatment of conditions mediated by tachykinins.
Type:
Grant
Filed:
October 12, 2001
Date of Patent:
October 10, 2006
Assignee:
SmithKline Beecham Corporation
Inventors:
Giuseppe Alvaro, Paolo Maragni, Marsia Tampieri
Abstract: The present invention provides compounds of formula (I): wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.
Type:
Grant
Filed:
October 7, 2005
Date of Patent:
September 19, 2006
Assignee:
SmithKline Beecham Corporation
Inventors:
Michael John Alberti, Stanley D. Chamberlain, Mui Cheung, Kristjan Gudmundsson, Philip Anthony Harris, Brian A. Johns, David Kendall Jung, Michael Robert Peel, Jennifer Badiang Stanford
Abstract: The invention relates to new methods of preparing substituted benzimidazole compounds, such as 2-bromo-5,6-dichlorobenzimidazole, which are useful in the preparation of compounds having antiviral activity.